Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN J ROSENBERG

Allopathic & Osteopathic Physicians Urology

NPI
1861488785
CMS profile
311678
Location
URBANDALE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$262.96

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Sumitomo Pharma America, Inc. $103.05 1
ABBVIE INC. $39.09 2
UROGEN PHARMA, INC. $31.28 1
Medtronic, Inc. $25.06 1
Ferring Pharmaceuticals Inc. $16.35 1
Astellas Pharma US Inc $16.31 1
Boston Scientific Corporation $15.09 1
Endo USA, Inc. $13.58 1
Ambu Inc. $3.15 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN J ROSENBERG

NPI 1861488785 · CMS profile ID 311678

Allopathic & Osteopathic Physicians / Urology

URBANDALE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861488785?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861488785?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861488785?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861488785?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $262.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UROGEN PHARMA, INC. $31.2810/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137933076 CMS
Boston Scientific Corporation $15.0908/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092533951 CMS
ABBVIE INC. $14.0207/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105975700 CMS
Endo USA, Inc. $13.5805/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138587060 CMS
Ambu Inc. $3.1504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134077048 CMS
ABBVIE INC. $25.0703/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105975698 CMS
Sumitomo Pharma America, Inc. $103.0502/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148911778 CMS
Ferring Pharmaceuticals Inc. $16.3502/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137506492 CMS
Astellas Pharma US Inc $16.3101/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139312516 CMS
Medtronic, Inc. $25.0601/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119519688 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $91.52 2
PY2020 $114.16 4
PY2021 $104.92 4
PY2022 $197.25 10
PY2023 $327.28 13
PY2024 $262.96 10
PY2025 $35.06 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,321.51 2
PY2023 Principal investigator $130,788.17 20
PY2022 Principal investigator $127,711.29 38
PY2021 Principal investigator $137,948.28 39
PY2020 Principal investigator $320,867.55 65
PY2019 Principal investigator $602,559.33 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $133.32 12/31/2021 Non-covered Recipient Entity
THE IOWA CLINIC P C
A PHASE IV, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING (ABPM) STUDY OF 16 WEEKS TREATMENT WITH ANDRODERM IN HYPOGONADAL MEN No dispute reported 06/30/2026 789015417
Principal investigator 1 UROVANT SCIENCES INC $7,646.40 12/15/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698771
Principal investigator 1 Allergan, Inc. $429.96 11/15/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789015415
Principal investigator 1 Astellas Pharma Global Development $9,367.00 11/09/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC UROLOGY
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801081207
Principal investigator 1 UROVANT SCIENCES INC $90.00 10/20/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698763
Principal investigator 1 UROVANT SCIENCES INC $2,790.90 10/15/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 837698767
Principal investigator 1 Astellas Pharma Global Development $3,926.00 10/06/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC UROLOGY
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801080901
Principal investigator 1 Astellas Pharma Global Development $3,926.00 10/06/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC UROLOGY
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801080931
Principal investigator 1 Dendreon Pharmaceuticals LLC $732.42 08/10/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851424793
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,029.95 07/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851424567
Principal investigator 1 Ferring International Pharmascience Center US $7,230.21 07/08/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) No dispute reported 06/30/2026 780071697
Principal investigator 1 Janssen Research & Development, LLC $10,500.00 06/21/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at Hi No dispute reported 06/30/2026 787746001
Principal investigator 1 Janssen Research & Development, LLC $3,803.00 06/16/2021 Non-covered Recipient Entity
The Ia Clnc
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 787784913
Principal investigator 1 Ferring Pharmaceuticals AS $104.00 06/15/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) No dispute reported 06/30/2026 780072337
Principal investigator 1 Ferring Pharmaceuticals AS $2,550.00 06/01/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) No dispute reported 06/30/2026 780072329
Principal investigator 1 Dendreon Pharmaceuticals LLC $6,393.40 05/18/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851424287
Principal investigator 1 Ferring Pharmaceuticals AS $650.00 05/18/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) No dispute reported 06/30/2026 780072327
Principal investigator 1 Astellas Pharma Global Development $1,850.00 05/17/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801080183
Principal investigator 1 Astellas Pharma Global Development $11,778.00 05/17/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801080185
Principal investigator 1 Astellas Pharma Global Development $1,387.00 05/17/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801080191
Principal investigator 1 Astellas Pharma Global Development $7,672.00 04/28/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801080047
Principal investigator 1 Dendreon Pharmaceuticals LLC $5,933.07 04/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851424233
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,158.68 04/23/2021 Non-covered Recipient Entity
The Iowa Clinic PC
BAY 1841788 AR/Antagonist Prostate CA Phase lll (ARAMIS) No dispute reported 06/30/2026 789125957
Principal investigator 1 Myovant Sciences Inc. $8,974.70 03/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
HERO STUDY GRANT No dispute reported 06/30/2026 835053263
Principal investigator 1 Myovant Sciences Inc. $950.00 03/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
HERO STUDY GRANT No dispute reported 06/30/2026 835053265
Principal investigator 1 Myovant Sciences Inc. $500.00 03/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
HERO STUDY GRANT No dispute reported 06/30/2026 835053267
Principal investigator 1 Myovant Sciences Inc. $600.00 03/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
HERO STUDY GRANT No dispute reported 06/30/2026 835053269
Principal investigator 1 Myovant Sciences Inc. $1,500.00 03/27/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
HERO STUDY GRANT No dispute reported 06/30/2026 835053271
Principal investigator 1 Astellas Pharma Global Development $11,778.00 03/17/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801079687
Principal investigator 1 Myovant Sciences Inc. $368.75 03/11/2021 Non-covered Recipient Entity
QCARE SITE SERVICES
HERO STUDY GRANT No dispute reported 06/30/2026 835053127
Principal investigator 1 Ferring Pharmaceuticals AS $2,004.21 03/09/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) No dispute reported 06/30/2026 780072287
Principal investigator 1 Dendreon Pharmaceuticals LLC $500.00 02/23/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851423925
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,660.00 02/23/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851423929
Principal investigator 1 Ferring Pharmaceuticals AS $1,132.56 02/16/2021 Non-covered Recipient Entity
THE IOWA CLINIC PC
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) No dispute reported 06/30/2026 780072267
Principal investigator 1 Allergan, Inc. $56.00 02/10/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Androderm 24-Hr ABPM No dispute reported 06/30/2026 789015413
Principal investigator 1 Astellas Pharma Global Development $3,926.00 01/28/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801079405
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,653.21 01/26/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851423795
Principal investigator 1 Allergan, Inc. $7,728.50 01/25/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence No dispute reported 06/30/2026 789015409
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,535.04 01/20/2021 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 851423531